Positive Electrostatic therapy; selective destruction of cancer tumors through their attraction to positive charges

Not Applicable

Recruiting

Conditions: C78.0
C79.2
C83.3
C22.1
C48.2
Condition 1: Malignant cancer with solid tumor. Condition 2: Malignant cancer with solid tumor. Condition 3: Malignant cancer with solid tumor. Condition 4: Malignant cancer with solid tumor. Condition 5: Malignant cancer with solid tumor. Condition 6: Malignant cancer with solid tumor. Condition 7: Malignant cancer with solid tumor. Condition 8: Malignant cancer with solid tumor. Condition 9: Malignant cancer with solid tumor. Condition 10: Malignant cancer with solid tumor.
Malignant neoplasm of breast
Secondary malignant neoplasm of liver and intrahepatic bile duct
Secondary and unspecified malignant neoplasm of lymph nodes
Secondary malignant neoplasm of lung

Registration Number: IRCT20190904044697N2

Lead Sponsor: Iran Nano Fund

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 50

Inclusion Criteria

Patients who have different types of cancer with solid tumors.
Patients who the biopsy of their tumors approved that the tumors are malignant.
Patients who their malignant tumors are not obey the normal cellular pathways of the tissue.
Patients with malignant tumors and highest levels of invasion are more appropriate for receiving treatment (i.e. triple negative breast cancer).
Patients who their tumors are not too deep and not too far from the surface of the body.
Pathological or radiological evidence of malignancy
Pathological or radiological evidence of progression of the disease despite classical treatments
Pathological or radiological evidence of recurrence of the disease despite classical treatments
At least 3 months life expectency
Patients with end-stage cancer who oncologists confirm that they did not profit from an alternative treatment, can include the study as a palliative therapy.

Exclusion Criteria

Patients who do not have appropriate general condition and need intensive care.
Patients with tumors which tumor cells are obey the normal cellular pathways of the tissue.
Patients who have different types of cancer which have no solid tumors.
Patients with benign tumors or the types of malignant tumors which are not invasive enough.
Patients who their tumors are deep and far from the surface of the skin.
Coagulation disorders (INR>1.5)
Pregnancy
Platelets<150000
Neutropenia (neutrophil<1500)
Anemia (Hemoglobin<12)
Acute Infection
Patients with pacemaker or any types of cardiac arrhythmia
Abnormal biochemistry or electrolyte of the serum.

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Tumor sizes, Serum Tumor Marker, Clinical Manifestation , Pathological and microscopical features, Immunohistochemistry markers. In patients with end-stage cancer, their clinical and quality of life changes are investigated and the electrostatic therapy are considered as a palliative therapy. Timepoint: 12 days. Method of measurement: Imaging modalities, Blood Test, Investigating of Clinical Manifestation, Immunohistochemistry, pathological and microscopical markers and cellular staining.

Secondary Outcome Measures